Zolgensma for free? Yes, but advocates worry about Novartis' lottery-style giveaway

At $2.1 million, Novartis' spinal muscular atrophy gene therapy Zolgensma holds the record for the world's most expensive treatment and it's only approved in the U.S. so far. But the Swiss drugmaker's plans for a worldwide lottery for free doses has some patient advocates worried.